Vet drugmakers get Warning Letters too

The FDA's marketing folks care about our pets. Regulatory Focus reports that the regulator has issued a Warning Letter to AB Science for marketing its canine tumor drug Kinavet for unapproved, off-label uses.

The Food and Drug Administration found fault with website copy that said the drug is “potentially well-suited for treating non-oncology diseases, such as canine atopic dermatitis or feline asthma,” and that off-label use studies supported this supposition.

RF says the FDA also highlighted that its case against AB Science is “particularly compelling” because Kinavet's approval “explicitly prohibits a company from allowing its drug to be used outside of its approved labeling.”

The manufacturer also failed to include risk information, such as the warning that people should not touch the drug because of its association with birth defects and other problems.

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.